TYROBP is a potential prognostic biomarker of clear cell renal cell carcinoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

TYROBP is a potential prognostic biomarker of clear cell renal cell carcinoma

Published:2020-10-31 Issue:12 Volume:10 Page:2588-2604
ISSN:2211-5463
Container-title:FEBS Open Bio
language:en
Short-container-title:FEBS Open Bio

Author:

Wu Ping¹,Xiang Tingting²,Wang Jing³,Lv Run⁴,Wu Guangzhen⁵^ORCID

Affiliation:

1. Department of Anesthesiology The First Affiliated Hospital of Dalian Medical University China

2. Department of Rehabilitation Liguang Rehabilitation Hospital of Dalian Development Zone China

3. Department of Neurobiology Harbin Medical University China

4. Anesthesiology Department Dalian Medical University China

5. Department of Urology The First Affiliated Hospital of Dalian Medical University China

Publisher

Wiley

Subject

General Biochemistry, Genetics and Molecular Biology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/2211-5463.12993

Reference49 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2. Histological Subtype is an Independent Predictor of Outcome for Patients With Renal Cell Carcinoma

3. Quantification of peripheral blood CD133 mRNA in identifying metastasis and in predicting recurrence of patients with clear cell renal cell carcinoma;Feng G;Urol Oncol: Semin Origin Invest,2014

4. Diagnostic and prognostic value of CEP55 in clear cell renal cell carcinoma as determined by bioinformatics analysis;Zhou L;Mol Med Rep,2019

5. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mining and exploration of appendicitis nursing targets: An observational study;Medicine;2024-06-28

2. Neoadjuvant camrelizumab (an anti-PD-1 antibody) plus chemotherapy or apatinib (a VEGFR-2 inhibitor) for initially unresectable stage II–III non-small-cell lung cancer: a multicentre, two-arm, phase 2 exploratory study;Signal Transduction and Targeted Therapy;2024-06-14

3. Diagnostic value of procalcitonin and hemocyte parameters in neonates with bloodstream infection: Role of activated hemocyte‐related genes;Pediatric Discovery;2024-05-23

4. Treg-Related Genes Representing a Potential Shared Biological Mechanism Between Clear Cell Renal Carcinoma and Obesity;Journal of the College of Physicians and Surgeons Pakistan;2024-02-01

5. TYROBP as a molecular target in cholangiocarcinoma, renal cancer and abdominal aortic aneurysm;Medicine;2024-01-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3